Showing results (11-20 of 39) with videos related to

Sort By:
Pageof 4
Annals of Translational Medicine|January 9, 2015
Clinical advances in the development of novel VEGFR2 inhibitorsCaterina Fontanella, Elena Ongaro, Silvia Bolzonello, et al.
Future Oncology (London, England)|November 12, 2014
Perspectives from American Society of Clinical Oncology: translational and clinical research highlights in breast and colorectal cancersCaterina Fontanella, Giuseppe Aprile, Mario Scartozzi, et al.
Cancer Treatment Reviews|May 25, 2016
Central nervous system involvement in breast cancer patients: Is the therapeutic landscape changing too slowly?Caterina Fontanella, Elisa De Carlo, Marika Cinausero, et al.
Expert Opinion on Drug Safety|May 5, 2017
The safety of antiangiogenic agents and PARP inhibitors in platinum-sensitive recurrent ovarian cancerDomenica Lorusso, Caterina Fontanella, Giuseppa Maltese, et al.
Clinical Colorectal Cancer|October 1, 2015
Maintenance Therapy in Colorectal Cancer: Moving the Artillery Down While Keeping an Eye on the EnemyGiuseppe Aprile, Francesco Giuliani, Stefania Eufemia Lutrino, et al.
Critical Reviews in Oncology/Hematology|April 15, 2014
Follow-up of patients with early breast cancer: is it time to rewrite the story?Fabio Puglisi, Caterina Fontanella, Gianmauro Numico, et al.
Cancers|November 27, 2025
Comparative Analysis of Maintenance Treatments in Patients with Newly Diagnosed Advanced Ovarian Cancer After First-Line Platinum-Based RegimensLorenzo Gasperoni, Luca Cancanelli, Andrea Ossato, et al.
Cancer Treatment Reviews|November 12, 2018
Post-neoadjuvant strategies in breast cancer: From risk assessment to treatment escalationGiacomo Pelizzari, Lorenzo Gerratana, Debora Basile, et al.
World Journal of Gastroenterology|July 13, 2013
Angiogenic inhibitors for older patients with advanced colorectal cancer: does the age hold the stage?Giuseppe Aprile, Caterina Fontanella, Eufemia Stefania Lutrino, et al.
Future Oncology (London, England)|July 23, 2016
A Delphi consensus and open debate on the role of first-line bevacizumab for HER2-negative metastatic breast cancerFabio Puglisi, Giancarlo Bisagni, Mariangela Ciccarese, et al.
Pageof 4